SMS Pharmaceuticals Limited — Others, 12-02-2025: Statement of deviation(s) or variation(s) under Reg. 32

SMS Pharmaceuticals Limited has provided a statement confirming that there is no deviation in the utilization of funds raised through its preferential issue completed on March 19, 2024, amounting to ₹28.58 crore. The funds were intended for capital expenditure to enhance production capacity and establish backward integration for key starting materials. The company’s Audit Committee and auditors reported no concerns regarding the fund usage for the quarter ending December 31, 2024. This clarity on fund utilization may positively influence investor sentiment by reinforcing confidence in SMS Pharmaceuticals' operational strategy and financial governance.